Hoosier Cancer Research Network (HCRN) is set to participate in ASCO GU 2025 in San Francisco from February 13-15, 2025, with HCRN-GU16-243 being presented as a Rapid Oral Abstract, and several other studies as poster presentations.

Study Presentations

Five Hoosier Cancer Research Network studies, HCRN-GU16-243, HCRN-GU16-260, HCRN-GU18-343, HCRN-GU20-436, and HCRN-GU21-517, will be presented during ASCO GU.

HCRN-GU16-243 is a randomized trial of regorafenib in combination with pembrolizumab or pembrolizumab monotherapy for patients with MSI-H colorectal cancer. The authors are Noah Hahn, Marianna Zahurak, Hristos Kaimakliotis, Timothy Masterson, Nabil Adra, David Chen, Alexander Kutikov, Daniel Geynisman, Woodson Smelser, Melissa Reimers, Christopher Anderson, Mark Stein, Alexander Baras, Gabriela Colocho, Deborah Schwartz, David McConkey, Sunil Patel, Bilal Rahim, Michael O’Donnell, and Max Kates.

• Session Title: Rapid Oral Abstract Session B: Urothelial Carcinoma
• Presentation Title: A phase 1/2 trial of durvalumab plus intravesical gemcitabine and docetaxel in BCG-unresponsive non-muscle invasive bladder cancer patients (HCRN GU16-243: ADAPT-BLADDER Cohort 4).
• Date: Friday, February 14 from 4:00 PM – 4:45 PM PST
• Abstract: https://meetings.asco.org/abstracts-presentations/242851

HCRN-GU16-260 has two abstracts that will be presented related to the study. This study is a prospective phase II trial of nivolumab in 120 treatment-naïve patients with clear cell renal cell carcinoma (ccRCC) and 40 treatment naïve patients with non-clear cell renal cell carcinoma (nccRCC). The authors of the abstract below are Razan Mohanna, Berkay Simsek, Nourhan El Ahmar, Opeyemi Jegede, Sayed Matar, Morgan Paul, Yasmin Nabil Laimon, Gabriel Roberti De Oliveira, Andrew Delcea, Toni Choueiri, David Braun, Naomi Haas, Hans Hammers, Mehmet Bilen, Mark Stein, Jeffrey Sosman, Catherine Wu, David McDermott, Michael Atkins, and Sabina Signoretti.

• Session Title: Poster Session C: Renal Cell Cancer; Penile, Testicular and Urethral Cancers
• Presentation Title: Association between PD-1 expression on tumor-infiltrating regulatory T cells and resistance to first-line nivolumab in advanced clear cell renal cell carcinoma: Insights from the HCRN GU16-260 clinical trial
• Poster Bd #: H25
• Date: Saturday, February 15 from 7:10 AM – 8:10 AM PST
• Abstract: https://meetings.asco.org/abstracts-presentations/242687

The authors of the other abstract related to HCRN-GU16-260 are Eddy Saad, Nourhan El Ahmar, Berkay Simsek, Opeyemi Jegede, Sayed Matar, Razan Mohanna, Emre Yekeduz, David McDermott, Elizabeth Plimack, Jeffrey Sosman, Naomi Haas, Michael Hurwitz, Hans Hammers, Eliezer Van Allen, Toni Choueiri, Michael Atkins, Sabina Signoretti, and David Braun.

• Session Title: Poster Session C: Renal Cell Cancer; Penile, Testicular and Urethral Cancers
• Presentation Title: A comprehensive evaluation of gene expression-based signatures for detecting tertiary lymphoid structures (TLS) in metastatic renal cell carcinoma (mRCC)
• Poster Bd #: H26
• Date: Saturday, February 15, 2025 from 7:10 AM – 8:10 AM PST
• Abstract: https://meetings.asco.org/abstracts-presentations/242688

HCRN-GU18-343 is a phase 2 study of cabozantinib in combination with atezolizumab as neoddjuvant treatment for muscle-invasive bladder cancer. The authors are Deepak Kilari, Aniko Szabo, Kathryn Bylow, Ariel Nelson, Peter Langenstroer, Scott Johnson, Arjun Sivaraman, Kenneth Jacobsohn, Chunkit Fung, Sindhuja Kadambi, Brian Rini, Melissa Reimers, Robert Alter, Asit Paul, Brendan Guercio, and Matthew Milowsky.

• Session Title: Poster Session B: Urothelial Carcinoma
• Presentation Title: A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer, (HCRN GU18-343) ABATE study
• Poster Bd #: F27
• Date: Friday, February 14 from 11:30 AM – 12:45 PM PST
• Abstract: https://meetings.asco.org/abstracts-presentations/242793

HCRN-GU20-436 is a phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations. The authors are Yu-Wei Chen, Lin Liu, Yuwei Cheng, Arlene Araneta, Neremiah Castano, Jennifer Gomez, Archana Ajmera, Huihui Ye, Karie Runcie, Deaglan McHugh, Kenneth Offit, Channing Paller, Naomi Haas, Robert Franklin, Roberto Pili, Juan Javier-Desloges, Christopher Kane, Tyler Seibert, Aditya Bagrodia, and Rana McKay.

• Session Title: Trials in Progress Poster Session A: Prostate Cancer
• Presentation Title: A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune)
• Poster Bd #: M28
• Date: Thursday, February 13 from 11:25 AM – 12:45 PM PST
• Abstract: https://meetings.asco.org/abstracts-presentations/243074

HCRN-GU21-517 is a phase 2 study of cabozantinib and nivolumab in metastatic castration resistant prostate cancer. The authors are Justine Panian, Yu-Wei Chen, Sharon Choi, Lin Liu, Minya Pu, Emily Pittman, Samuel Pena, Qian Qin, Tian Zhang, Hamid Emamekhoo, Joshua Lang, Akash Patnaik, and Rana McKay.

• Session Title: Trials in Progress Poster Session A: Prostate Cancer
• Presentation Title: A phase 2 study of cabozantinib and nivolumab in metastatic castration resistant prostate cancer (CANOPY)
• Poster Bd #: M21
• Date: Thursday, February 13 from 11:25 AM – 12:45 PM PST
• Abstract: https://meetings.asco.org/abstracts-presentations/243061

About Hoosier Cancer Research Network:

Hoosier Cancer Research Network conducts innovative cancer clinical trials in collaboration with more than 100 academic and community clinical research sites across the United States. Our studies are designed by cancer researchers from our member institutions. The HCRN staff includes 55 team members who work together to support all aspects of the studies we manage, from the time we receive the initial concept from a researcher through the final publication of the study results. Currently, we are supporting more than 70 clinical trials across a wide range of cancer types. Over our 40-year history, more than 10,000 participants in have enrolled in our clinical trials, leading to important discoveries that help cancer patients live longer and better after their cancer diagnosis